Trial Profile
An Exploratory Evaluation of Interleukin 28B (IL28B) Genotype, Single Nucleotide Polymorphisms (SNP) of rs12356193, Protein and RNA Biomarkers in Serum Samples (Stored, Already Obtained From Completed Studies) From Subjects With HBe-antigen Positive or Negative Chronic Hepatitis B, Who Have Completed Therapy for Hepatitis B With Pegasys +/- Lamivudine.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Lamivudine (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Sponsors Roche
- 25 Apr 2014 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 08 Nov 2012 New trial record